ARQT

9.43

1.84% 0.17

Handel nachbörslich: 9.43

Arcutis Biotherapeutics Inc (ARQT)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ARQT? Forum Prognose

Schlusskurs vom Vortag:

$9.26

Offen:

$9.27

24-Stunden-Volumen:

1.94M

Relative Volume:

0.97

Marktkapitalisierung:

$1.08B

Einnahmen:

$59.61M

Nettoeinkommen (Verlust:

$-262.14M

KGV:

-1.7022

EPS:

-5.54

Netto-Cashflow:

$-247.49M

1W Leistung:

-13.01%

1M Leistung:

+8.14%

6M Leistung:

+2.50%

1J Leistung:

+362.25%

1-Tages-Spanne:

$8.90

$9.46

1-Wochen-Bereich:

$8.90

$10.76

52-Wochen-Spanne:

$1.76

$13.17

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Firmenname

Arcutis Biotherapeutics Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

805-418-5006

Adresse

3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA

Mitarbeiter

296

Twitter

@ArcutisBio

Nächster Verdiensttermin

2024-12-06

Neueste SEC-Einreichungen

ARQT's Discussions on Twitter

Vergleichen Sie ARQT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ARQT	9.43	1.08B	59.61M	-262.14M	-247.49M	-5.54
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-01-03	Hochstufung	Mizuho	Neutral → Buy
2023-10-26	Herabstufung	Mizuho	Buy → Neutral
2023-10-13	Herabstufung	Goldman	Buy → Neutral
2022-09-07	Eingeleitet	Needham	Buy
2022-03-17	Eingeleitet	Goldman	Buy
2021-06-30	Eingeleitet	Mizuho	Buy
2021-05-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-11-09	Hochstufung	Goldman	Neutral → Buy
2020-10-08	Eingeleitet	Truist	Buy
2020-02-25	Eingeleitet	Cantor Fitzgerald	Overweight
2020-02-25	Eingeleitet	Cowen	Outperform
2020-02-25	Eingeleitet	Goldman	Neutral
2020-02-25	Eingeleitet	Guggenheim	Buy

Alle ansehen

Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten

10:29 AM

Arcutis Biotherapeutics: What Lies Ahead (NASDAQ:ARQT) - Seeking Alpha

10:29 AM

Nov 16, 2024

Long Term Trading Analysis for (ARQT) - Stock Traders Daily

Nov 16, 2024

Nov 15, 2024

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up? - Seeking Alpha

Nov 15, 2024

Nov 14, 2024

Insider Selling: Director Terrie Curran Sells Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Arcutis Biotherapeutics director sells $94,238 in stock - Investing.com

Nov 13, 2024

Rubric Capital Management LP's Strategic Acquisition in Arcutis Biotherapeutics Inc - GuruFocus.com

Nov 13, 2024

Arcutis Biotherapeutics director sells $94,238 in stock By Investing.com - Investing.com UK

Nov 13, 2024

Arcutis' ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour - The Manila Times

Nov 13, 2024

Arcutis' ZORYVE Wins Glamour's Best Eczema Treatment Award, Targets 26M Patient Market | ARQT Stock News - StockTitan

Nov 13, 2024

Nov 12, 2024

GSA Capital Partners LLP Has $2.21 Million Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat

Nov 12, 2024

Nov 11, 2024

Chronic Hand Eczema Pipeline Update 2024: FDA Approvals, - openPR

Nov 11, 2024

Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - Yahoo Finance

Nov 11, 2024

Nov 08, 2024

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 08, 2024

Nov 07, 2024

Earnings call: Arcutis Biotherapeutics reports robust growth for ZORYVE - Investing.com

Nov 07, 2024

Arcutis Biotherapeutics (NASDAQ:ARQT) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Nov 07, 2024